Short Interest Update on Ironwood Pharmaceuticals (IRWD)

Ironwood Pharmaceuticals (IRWD) : The bears are holding on to their shorts in Accenture Plc with 11 more days remaining for them to cover their positions. The bearish positions have increased from 13,975,110 on Jul 29, 2016, to 14,140,844, on August 15, 2016. Daily, 1,246,021 shares are traded, which shows the high interest of the traders in the stock. The net addition of short open interest is 165,734 shares, which is an increase of just 1.2%. The total short interest of 11.1% of the float indicates that there arent many bears on this stock at the current prices. The short interest information was released on Wednesday Aug 24th after the market close.

Ironwood Pharmaceuticals (NASDAQ:IRWD): The stock opened at $13.98 on Wednesday but the bulls could not build on the opening and the stock topped out at $14.17 for the day. The stock traded down to $13.47 during the day, due to lack of any buying support eventually closed down at $13.50 with a loss of -3.36% for the day. The stock had closed at $13.97 on the previous day. The total traded volume was 1,314,583 shares.


In a related news,The director of Ironwood Pharmaceuticals Inc, Olanoff Lawrence S sold 2,200 shares at $12.92 on June 3, 2016. The Insider selling transaction had a total value worth of $28,424. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. The Company has a product, linaclotide, which is available in the United States and Mexico under the brand name LINZESS, and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *